| 000 | 01599 a2200445 4500 | ||
|---|---|---|---|
| 005 | 20250513202858.0 | ||
| 264 | 0 | _c20000510 | |
| 008 | 200005s 0 0 eng d | ||
| 022 | _a0006-8993 | ||
| 024 | 7 |
_a10.1016/s0006-8993(99)02363-x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aCusack, B | |
| 245 | 0 | 0 |
_aEffects of a novel neurotensin peptide analog given extracranially on CNS behaviors mediated by apomorphine and haloperidol. _h[electronic resource] |
| 260 |
_bBrain research _cFeb 2000 |
||
| 300 |
_a48-54 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aApomorphine _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aBehavior, Animal _xdrug effects |
| 650 | 0 | 4 |
_aBody Temperature _xdrug effects |
| 650 | 0 | 4 |
_aCatalepsy _xchemically induced |
| 650 | 0 | 4 |
_aClozapine _xpharmacology |
| 650 | 0 | 4 |
_aHaloperidol _xantagonists & inhibitors |
| 650 | 0 | 4 | _aInjections, Intraperitoneal |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMice |
| 650 | 0 | 4 |
_aMotor Activity _xdrug effects |
| 650 | 0 | 4 |
_aNeurotensin _xadministration & dosage |
| 650 | 0 | 4 |
_aPeptide Fragments _xadministration & dosage |
| 650 | 0 | 4 | _aRats |
| 650 | 0 | 4 | _aRats, Sprague-Dawley |
| 650 | 0 | 4 | _aTime Factors |
| 700 | 1 | _aBoules, M | |
| 700 | 1 | _aTyler, B M | |
| 700 | 1 | _aFauq, A | |
| 700 | 1 | _aMcCormick, D J | |
| 700 | 1 | _aRichelson, E | |
| 773 | 0 |
_tBrain research _gvol. 856 _gno. 1-2 _gp. 48-54 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/s0006-8993(99)02363-x _zAvailable from publisher's website |
| 999 |
_c10631953 _d10631953 |
||